Methotrexate is a dihydrofolate reductase inhibitor that interferes with DNA synthesis, DNA repair, and cellular replication. We present the first adult case of a patient who received intravenous contrast prior to administration of high-dose methotrexate, who subsequently experienced delayed methotrexate clearance and renal impairment necessitating the use of glucarpidase. This case displays a possible correlation between intravenous radiographic contrast administration and resulting toxicity due to delayed methotrexate clearance.
Rahiem AhmedYAAHasanY. Prevention and management of high dose methotrexate toxicity. J Cancer Sci Ther2013; 5: 106–112.
2.
HowardSCMcCormickJPuiCHet al.Preventing and managing toxicities of high-dose methotrexate. Oncologist2016; 21: 1471–1482.
3.
YanagimachiMGotoHKanekoTet al.Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate. Int J Hematol2013; 98: 702–707.
4.
FermianoMBergsbakenJKolesarJM. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. Am J Health Syst Pharm2014; 71: 793–798.
5.
MoosSIvan VemdeDNStokerJet al.Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol2013; 82: e387–e399.
6.
HoYFHsiehKLKungFLet al.Nephrotoxic polypharmacy and risk of contrast medium-induced nephropathy in hospitalized patients undergoing contrast-enhanced CT. Am J Roentgenol2015; 205: 703–708.
7.
BhattSRajpalNRathiVet al.Contrast induced nephropathy with intravenous iodinated contrast media in routine diagnostic imaging: an initial experience in a tertiary care hospital. Radiol Res Pract2016; 2016: 8792984–8792984.
8.
HarnedTMMascarenhasL. Severe methotrexate toxicity precipitated by intravenous radiographic contrast. J Pediatr Hematol Oncol2007; 29: 496–499.
9.
FongCMLeeAC. High-dose methotrexate-associated acute renal failure may be an avoidable complication. Pediatr Hematol Oncol2006; 23: 51–57.
10.
WidemannBCSchwartzSJayaprakashNet al.Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy2014; 34: 427–439.
11.
WiczerTDotsonETutenAet al.Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract2016; 22: 430–436.
12.
TuffahaHWOmarSA. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract2011; 17: 136–140.
13.
KantarjianHThomasDO’BrienSet al.Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphoblastic leukemia. Cancer2004; 101: 2788–2801.
